Rigel Pharmaceuticals Inc. at Cantor Fitzgerald Global Healthcare Conference (Live)
September 26, 2017 at 2:15 p.m. ET
Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP
. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia (AIHA)
and IgA nephropathy (IgAN)
. In addition, Rigel has product candidates in development with partners BerGenBio AS
, Daiichi Sankyo
, and Aclaris Therapeutics
Recent NewsMore »
|09/19/17||Rigel to Present at Cantor Fitzgerald Global Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif., Sept. 19, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, September 26, 2017 at 2:15pm EDT.
To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website... |
|08/25/17||Rigel Welcomes Brian Kotzin, M.D. to Board of Directors|
|SOUTH SAN FRANCISCO, Calif., Aug. 25, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Brian L. Kotzin, M.D. has been appointed to Rigel's board of directors. A well-respected former professor and clinical researcher, Dr. Kotzin brings to Rigel's board three decades of experience in the areas of immunology and inflammation.
"We are excited to welcome Dr. Kotzin to our board, and we feel confident that his leadership will be of great value to Rigel," said Ra... |
|08/01/17||Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update|
|Conference Call and Webcast Today at 5:00PM Eastern Time
SOUTH SAN FRANCISCO, Calif., Aug. 1, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2017.
On June 19, 2017, Rigel announced the U.S Food & Drug Administration (FDA) had accepted for filing its New Drug Application (NDA) for the use of TAVALISSE™ (fostamatinib disodium) in patients with chronic or persis... |
Upcoming EventsMore »
|Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.|